Flash FinanceUS
Market open S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Autolus Therapeutics plc (AUTL)

Autolus Therapeutics Q3 revenue rises 95% to $41.2 million; raises 2026 outlook

Positive Impact 4 of 5 guidance

Autolus reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up from $21.1 million a year earlier, and now expects full-year 2026 AUCATZYL net product revenue at or above the upper end of $150 million, up from prior guidance. The company also reported a narrower net loss and said its cash is expected to fund operations into Q2 2028.

Key points

  • Q3 2026 net product revenue was $41.2 million versus $21.1 million in Q3 2025.
  • Gross margin was 57%, up from 55% in Q2 2026 and negative in Q3 2025.
  • Net loss was $55.1 million, compared with $79.1 million in the year-earlier quarter; loss per share was $(0.21) versus $(0.30).
  • Cash, cash equivalents and marketable securities were $248.4 million at September 30, 2026, up from $201.6 million at June 30, 2026, mainly from Perceptive senior secured note inflows.

The filing

CompanyAutolus Therapeutics plc (AUTL)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:25 AM ET
Accession number0001730463-26-000141

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:32 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.